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Abstract: Two novel series of N-sulfonylamidino pyrimidine derivatives were synthesized via Cu-catalyzed three-component reaction of 
propargylated nucleobases with different benzenesulfonyl azides and amines. In this way 4-acetamido, 4-methyl and 4-carboxybenzenesulfonyl 
amidine products 15–26 in the uracil series and 4-acetamidobenzenesulfonyl amidine derivatives 27–29 in the cytosine series were prepared 
in 34−69 % yields. Attempts to prepare N-sulfonylamidino cytosine derivatives in reaction with 4-methylbenzenesulfonyl azide were 
unsuccessful. The cytosine derivatives 32 and 33 were prepared from the N-sulfonylamidino uracil derivatives via the C4 triazole intermediates.  
The prepared N-sulfonylamidino pyrimidine derivatives 1–28 were tested for the antiproliferative activity on a panel of seven tumor cell lines 
of different histological origin (HeLa, Caco-2, NCI-H358, Raji, HuT78, K562, Jurkat) and on normal MDCK I cells. Most of the synthesized 
compounds showed antiproliferative activity on the tested cell lines.  
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INTRODUCTION 
N the last two decades, our group has been intensively 
involved in the design and synthesis of a new series of 
N-sulfonyl nucleobase derivatives that exhibit antitumor 
activity.[1–4] We have shown that N-1-sulfonylpyrimidine 
derivatives have strong antiproliferative activity on 
human tumor cell lines and an ability to induce apoptosis 
in the treated tumor cells.[5–10] In vivo experiments 
showed that some N-sulfonylcytosine derivatives had 
strong antitumor activity against mouse mammary 
carcinoma.[9,11–14] 
 Recently, we reported an efficient multicomponent 
synthesis of the new N-sulfonylamidino thymine derivatives  
 
1−14 using Cu(I) catalyzed three component reactions of 1-
propargyl thymine, selected benzenesulfonyl azides, and 
amines or ammonium salts (Table 1).[15] We have shown 
that this one-pot three component reaction appears to be 
advantageous for the preparation of variously substituted 
N-sulfonylamidino thymine derivatives in moderate to 
good yields and opens the way for the preparation of the 
libraries of other nucleobase N-sulfonylamidino derivatives 
as possible biologically active molecules. 
 As the next step in our research, we report here on 
the synthesis of novel N-sulfonylamidine derivatives in 
uracil and cytosine series and the results of in vitro activity 
of N-sulfonylamidine-derived pyrimidine analogues on the 
growth of different tumor cell lines. 
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EXPERIMENTAL 
General  
Solvents were distilled from appropriate drying agents 
shortly before use. TLC was carried out on DC-plastikfolien 
Kieselgel 60 F254 and preparative thick-layer (2 mm) chroma-
tography was done on Merck 60 F254 (Merck KGaA, Darm-
stadt, Germany). Purification for the removal of copper 
particles was carried out on short columns filled with neutral 
and activated Al2O3 (particle size 0.05–0.15 mm). Melting 
points were determined on a Kofler hot-stage apparatus and 
were uncorrected. UV spectra [log ε / dm3 mol–1 cm–1, λmax / 
nm] were taken on a Philips PU8700 UV/VIS spectrophotom-
eter. IR spectra [νmax / cm–1] were recorded as KBr pellets on 
a Perkin-Elmer 297 spectrophotometer. 1H and 13C NMR 
spectra were recorded in DMSO-d6 on Bruker AV300 and 
AV600 MHz spectrometers (Bruker BioSpin GmbH, Rhein-
stetten, Germany) using TMS or DMSO-d6 as the internal 
standard. Elemental analyses were performed by the Applied 
Laboratory Research Department at INA, d.d. Research and 
Development Sector, Central Analytical Laboratory. 
General Procedures for the Preparation 
of N-Sulfonyl Amidines (Table 1) 
 
METHOD A 
To a stirred mixture of alkyne (1 mmol), sulfonyl azide (1.2 
mmol) and CuI (0.1 mmol) in dry THF (2 mL) amine 
nucleophile (1.2 mmol) was slowly added. The reaction 
mixture was stirred for 24 h at room temperature and 
diluted with a small amount of cold methanol. The product 
was collected by filtration and dissolved in hot MeOH. The 
crude amidine product was filtered through a short Al2O3 
column, evaporated and the analytically pure product was 
obtained by recrystallization using methanol. 
 
METHOD B 
To a stirred mixture of alkyne (1 mmol), CuI (0.1 mmol) and 
amine / ammonium salt (1 mmol) in dry CH2Cl2 (2−5 mL) 
triethylamine (1.5 mmol) was slowly added and the color of 
the suspension turned to a light yellow. After that, sulfonyl 
azide (1 mmol) was added. The reaction mixture was stirred 
for 24 h at room temperature and diluted with a small 
amount of cold methanol. The product was collected by 
filtration and dissolved in hot MeOH. The crude amidine 
product was filtered through a short Al2O3 column, 
evaporated and the analytically pure product was obtained 
by recrystallization using methanol. 
 
METHOD C 
To a stirred mixture of alkyne (1 mmol), sulfonyl azide (1.2 
mmol) and CuI (0.1 mmol) in THF (2 mL) cooled to 0 °C, 
amine nucleophile (2 mmol) was slowly added. The 
reaction mixture was stirred for 24 h (4 h in the case of 
compound 25) at room temperature, dissolved in MeOH 
and filtered through a short Celite column. The filtrate was 
partially evaporated and the residue was filtered off. The 
crude product was dissolved in 5 % aq. NaHCO3 and the 
water solution was washed with dichloromethane and 
ethyl acetate. The water phase was neutralized with 5 % 
CH3COOH and partially evaporated. The product was 
collected by filtration and recrystallized from methanol. 
 
N1,N1-DIISOPROPYL-N2-(4-ACETAMIDOBENZENE-1-
SULFONYL)-3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-
1(2H)-YL)PROPANAMIDINE (15) METHOD A 
White solid (69 %); Rf = 0.79 (CH2Cl2 / MeOH 9 : 1); m.p. =  
229 °C; UV (MeOH): λmax / nm: 264 (log ε / dm–3 mol–1cm–1: 
4.6); IR (KBr) ν / cm–1: 3310 (m), 3187 (m), 3046 (m), 2975 
(m), 1714 (s), 1680 (s), 1552 (s), 1454 (s), 1399 (s), 1375 (s), 
1257 (s), 1260 (s), 1136 (s), 1081 (s), 1054 (s); 1H NMR (600 
MHz, DMSO-d6) δ / ppm: 11.32 (brs, 1H, NH-3'), 10.22 (s, 
1H, NH-Ac), 7.72 (s, 4H, Ar), 7.45 (d,1H, J6',5' = 7.8 Hz, H-6'), 
5.63 (d, 1H, J5',6' = 7.8 Hz, H-5'), 4.27 (m, 1H, CH-(CH3)2), 3.95 
(t, 2H, J3,2 = 7.4 Hz, CH2-3), 3.65 (m, 1H, CH-(CH3)2), 3.20 (t, 
2H, J2,3 = 7.4 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.20 (pt, 12H, 
J = 6.5 Hz, CH-(CH3)2); 13C NMR (150 MHz, DMSO-d6) δ / 
ppm: 168.8 (s, CO-CH3), 163.7 (s, C-4'), 161.6 (s, C-1), 151.0 
(s, C-2'), 145.0 (d, C-6'), 141.9 (s, Ar), 138.1 (s, Ar), 126.5 (d, 
Ar), 118.3 (d, Ar), 101.6 (d, C-5'), 50.2 (d, CH-(CH3)2), 47.3 
(d, CH-(CH3)2), 45.3 (t, CH2-3), 31.3 (t, CH2-2), 24.0 (q, CO-
CH3), 20.1 (q, CH-(CH3)2), 19.6 (q, CH-(CH3)2). Anal. Calcd. 
mass fractions of elements, w / %, for C21H29N5O5S x 0.5H2O 
(Mr = 472.56) are: C, 53.37; H, 6.40; N, 14.82; S, 6.78; found: 
C, 53.59; H, 6.47; N, 15.06; S, 6.54. 
 
N1,N1-DIETHYL-N2-(4-ACETAMIDOBENZENE-1-SULFONYL)-
3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-1(2H)-
YL)PROPANAMIDINE (16) METHOD A 
White solid (57 %); m.p. = 229–231 °C; Rf = 0.58 (CH2Cl2 / 
MeOH 9 : 1); UV (MeOH): λmax / nm: 264 (log ε / dm–3 mol–1 
cm–1 : 4.1); IR (KBr) ν / cm–1:  3311 (m), 3276 (m), 3190 (w), 
3053 (m), 2975 (w), 1698 (s), 1680 (s), 1565 (s), 1532 (s), 
1317(s), 1239 (s), 1130 (m), 1077 (m); 1H NMR (300 MHz, 
DMSO-d6) δ / ppm: 11.34 (brs, 1H, NH-3'), 10.24 (s, 1H, NH-
Ac), 7.75 (d, 2H, J = 8.9 Hz, Ar), 7.70 (d, 2H, J = 8.9 Hz, Ar), 
7.43 (d,1H, J6',5' = 7.9 Hz, H-6'), 5.62 (d, 1H, J5',6' = 7.9 Hz, H-
5'), 3.97 (t, 2H, J3,2 = 7.3 CH2-3), 3.49 (q, 2H, J = 6.9 CH2-CH3), 
3.38 (q, 2H, J = 6.9 CH2-CH3), 3.15 (t, 2H, J2,3 = 7.3 Hz, CH2-
2), 2.07 (s, 3H, CO-CH3), 1.16 (t, 3H, J = 7.8 Hz, CH2-CH3), 
1.01 (t, 3H, J = 7.8 Hz, CH2-CH3), 13C NMR (150 MHz, DMSO-
d6) δ / ppm: 168.9 (s, CO-CH3), 163.7 (s, C-4'), 162.9 (s, C-1), 
151.0 (s, C-2'), 144.9 (d, C-6'), 142.0 (s, Ar), 138.1 (s, Ar), 
126.6 (d, Ar), 118.4 (d, Ar), 101.7 (d, C-5'), 45.4 (t, CH2-3), 
43.2 (t, CH2-CH3), 43.0 (t, CH2-CH3), 29.9 (t, CH2-2), 24.1 (q, 
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CO-CH3), 13.9 (q, CH2-CH3), 11.8 (q, CH2-CH3). Anal. Calcd. 
mass fractions of elements, w / %, for C19H25N5O5S (Mr = 
435.49) are: C, 52.40; H, 5.78; N, 16.08; S, 7.36; found: C, 
52.16; H, 5.76; N, 16.30; S, 7.07. 
 
N1-ISOPROPYL-N2-(4-ACETAMIDOBENZENE-1-SULFONYL)-
3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-1(2H)-
YL)PROPANAMIDINE (17) METHOD A 
White solid (50 %); m.p. = 146 °C; Rf = 0,74 (CH2Cl2 / MeOH 
9 : 1); UV (MeOH): λmax / nm: 262 (log ε / dm–3 mol–1 cm–1: 
4,5); IR (KBr) ν / cm–1: 3499 (m), 3062 (m), 2980 (m), 2928 
(m), 1697 (s), 1673 (s), 1596 (m), 1562 (m), 1541 (m), 1366 
(m), 1328 (m), 1229 (m), 1137 (m), 1088 (m); 1H NMR (300 
MHz, DMSO-d6) δ / ppm: 11.24 (brs, 1H, NH-3'), 10.27 (s, 
1H, NH-Ac), 8.68 (d, 1H, J = 7.1 Hz, NH-CH), 7.73 (d, 2H, J = 
8.8 Hz, Ar), 7.71 (d, 2H, J = 8.8 Hz, Ar), 7.38 (d,1H, J6',5' = 7.8 
Hz, H-6'), 5.55 (d, 1H, J5',6' = 7.8 Hz, H-5'), 4.02 (t, 2H, J3,2 = 
6.1 Hz, CH2-3), 3.86 (m, 1H, CH-(CH3)2), 2.89 (t, 2H, J2,3 = 6.1 
Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.01 (d, 6H, J = 6.5 Hz, CH-
(CH3)2), 13C NMR (150 MHz, DMSO-d6) δ / ppm: 169.3 (s, CO-
CH3), 164.3 (s, C-4'), 163.6 (s, C-1), 151.2 (s, C-2'), 145.7 (d, 
C-6'), 142.0 (s, Ar), 138.6 (s, Ar), 127.1 (d, Ar), 118.8 (d, Ar), 
101.5 (d, C-5'), 45.8 (t, CH2-3), 43.2 (d, CH-(CH3)2), 33.3 (t, 
CH2-2), 24.1 (q, CO-CH3), 21.1 (q, CH-(CH3)2). Anal. Calcd. 
mass fractions of elements, w / %, for C18H23N5O5S × 1.5H2O 
(Mr = 448.49) are: C, 48.20; H, 5.84; N, 15.62; S, 7.15; found: 
C, 48.29; H, 5.48; N, 15.76; S, 7.13. 
 
N1-CYCLOPENTYL-N2-(4-ACETAMIDOBENZENE-1-
SULFONYL)-3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-
1(2H)-YL)PROPANAMIDINE (18) METHOD A 
White solid (48 %); m.p. = 147–149 °C; Rf = 0.43 (CH2Cl2 / 
MeOH 9 : 1); UV (MeOH): λmax / nm: 263 (log ε / dm–3 mol–1 
cm–1: 4.5); IR (KBr) ν / cm–1 3327 (s), 3012 (m), 2959 (m), 
1696 (s), 1672 (s), 1251 (s), 1264 (s), 1255 (s), 1148 (m); 1H 
NMR (300 MHz, DMSO-d6) δ / ppm: 11.22 (brs, 1H, NH-3'), 
10.24 (s, 1H, NH-Ac), 8.72 (brs, 1H, NH-cyclopentyl), 7.74 (d, 
2H, J = 8.9 Hz, Ar), 7.70 (d, 2H, J = 8.9 Hz, Ar), 7.37 (d,1H, 
J6',5' = 7.8 Hz, H-6'), 5.55 (d, 1H, J5',6' = 7.8 Hz, H-5'), 3.99 (t, 
2H, J3,2 = 6.2 Hz, CH2-3), 3.98 (m, 1H, CH-cyclopentyl), 2.91 
(t, 2H, J2,3 = 6.2 Hz, CH2-2), 2.07 (s, 3H, CH3-CO), 1.75 (m, 2H, 
CH2-cyclopentyl), 1.56 (m, 2H, CH2-cyclopentyl), 1.45 (m, 
2H, CH2-cyclopentyl), 1.38 (m, 2H, CH2-cyclopentyl); 13C 
NMR (150 MHz, DMSO-d6) δ / ppm: 168.8 (s, CO-CH3), 164.0 
(s, C-4'), 163.8 (s, C-1), 150.7 (s, C-2'), 145.2 (d, C-6') 141.9 
(s, Ar), 138.1 (s, Ar), 126.6 (d, Ar), 118.3 (d, Ar), 101.0 (d, C-
5'), 52.9 (d, CH-cyclopentyl), 45.7 (t, CH2-3), 33.1 (t, CH2-2), 
31.4 (t, CH2-cyclopentyl), 24.1 (q, CO-CH3), 23.5 (t, CH2-
cyclopentyl). Anal. Calcd. mass fractions of elements, w / 
%, for C20H25N5O5S x H2O (Mr = 465.52) are: C, 51.60; H, 
5.84; N, 15.04; S, 6.88; found: C, 51.53; H, 5.71; N, 15.08; 
S, 6.77. 
 
N1-(QUINOLIN-6-YL)-N2-(4-ACETAMIDOBENZENE-1-
SULFONYL)-3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-
1(2H)-YL)PROPANAMIDINE (19) METHOD A 
Pale yellow solid (49 %); m.p. = 221–223 °C; Rf = 0.43 (CH2Cl2 
/ MeOH 9 : 1); UV (MeOH): λmax / nm: 262 (log ε / dm–3 mol–
1 cm–1 : 4.4); IR (KBr) ν / cm–1: 3317 (m), 3104 (m), 2970 (m), 
2765 (m), 1695 (s), 1676 (s), 1553 (s), 1442 (s), 1276 (s), 
1147 (s), 1089 (s); 1H NMR (300 MHz, DMSO-d6)  
δ / ppm: 11.26 (brs, 1H, NH-3'), 10.70 (brs, 1H, NH-
quinolinyl), 10.30 (s, 1H, NH-Ac), 8.84−7.48 (m, 10H, Ar, 
quinolinyl), 7.54 (d, 1H, J6',5' = 7.7 Hz, H-6'), 5.56 (d, 1H, J5',6' 
= 7.7 Hz, H-5'), 4.20 (brt, 2H, CH2-3), 3.21 (brt, 2H, CH2-2), 
2.08 (s, 3H, CO-CH3); 13C NMR (150 MHz, DMSO-d6) δ / ppm: 
169.0 (s, CO-CH3), 163.8 (s, C-4'), 163.1 (s, C-1), 151.0 (s, C-
2'), 150.1 (d, Ar), 145.3 (s, Ar), 145.0 (d, C-6'), 142.5 (s, Ar), 
137.1 (s, Ar), 135.7 (s, Ar), 135.6 (d, Ar), 129.3 (d, Ar), 127.7 
(s, Ar) 127.0 (d, Ar), 125.2 (d, Ar), 122.0 (d, Ar), 119.1 (d, Ar), 
118.5 (d, Ar), 101.3 (d, C-5') 45.9 (t, CH2-3), 34.2 (t, CH2-2), 
24.1 (q, CO-CH3). Anal. Calcd. mass fractions of elements, w 
/ %, for C24H22N6O5S × 1.5 H2O (Mr = 533.56) are: C, 54.03; 
H, 4.72; N, 15.75; S, 6.01; found: C, 53.86; H, 4.69; N, 15.70; 
S, 6.30. 
 
N1-(4-CYANOBENZYL)-N2-(4-ACETAMIDOBENZENE-1-
SULFONYL)-3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-
1(2H)-YL)PROPANAMIDINE (20) METHOD B 
White solid (34 %); m.p. = 230−234 °C; Rf = 0.47 (CH2Cl2 / 
MeOH 9 : 1); UV (MeOH): λmax / nm: 237 and 264 (log ε / 
dm–3 mol–1 cm–1: 3.7 and 3.7); IR (KBr) ν / cm–1: 3310 (s), 
3014 (m), 2973 (m), 2816 (m), 2221 (w), 1698 (s), 1666 (s), 
1526 (s), 1268 (s), 1139 (s), 1092 (m); 1H NMR (300 MHz, 
DMSO-d6) δ / ppm: 11.26 (brs, 1H, NH-3'), 10.24 (s, 1H, NH-
Ac), 9.35 (brs, 1H, NH-CH2), 7.72 (d, 2H, J = 8.0 Hz, Ar), 7.63 
(d, 2H, J = 8.7 Hz, Ar), 7.60 (d, 2H, J = 8.7 Hz, Ar), 7.38 (d, 1H, 
J6',5' = 7.8 Hz, H-6'), 7.36 (d, 2H, J = 8.0 Hz, Ar), 5.52 (d, 1H, 
J5',6' = 7.8 Hz, H-5'), 4.37 (t, 2H, J = 5,4 Hz, NH-CH2), 4.05 (t, 
2H, J3,2 = 6.0 Hz, CH2-3), 3.01 (t, 2H, J2,3 = 6.0 Hz, CH2-2), 2.07 
(s, 3H, CO-CH3); 13C NMR (150 MHz, DMSO-d6) δ / ppm: 
168.8 (s, CO-CH3), 165.0 (s, C-4'), 163.7 (s, C-1), 150.7 (s, CO-
2'), 145.0 (d, C-6'), 143.1 (s, Ar), 142.0 (s, Ar), 137.6 (s, Ar), 
132.1 (d, Ar), 128.5 (d, Ar), 126.6 (d, Ar), 118.7 (s, CN), 118.3 
(d, Ar), 109.9 (s, Ar), 101.2 (d, C-5) 45.7 (t, NH-CH2), 44.5 (t, 
CH2-3), 33.0 (t, CH2-2), 24.0 (q, CO-CH3). Anal. Calcd. mass 
fractions of elements, w / %, for C23H22N6O5S (Mr = 494.52) 
are: C, 55.86; H, 4.48; N, 16.99; S, 6.48; found: C, 55.68; H, 
4.38; N, 16.98; S, 6.31. 
 
N-(4-ACETAMIDOBENZENE-1-SULFONYL)-3-(2,4-DIOXO-
3,4-DIHYDROPYRIMIDINE-1(2H)-YL)PROPANAMIDINE 
(21) METHOD B 
White solid (47 %); m.p. = 215 °C; Rf = 0.35 (CH2Cl2 / MeOH 
9 : 1); UV (MeOH): λmax / nm: 263 (log ε / dm–3 mol–1 cm–1: 4.5);  
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IR (KBr) ν / cm–1: 3369 (s), 3204 (s), 3091 (m), 2955 (w), 2798 
(w), 1707 (s), 1669 (s), 1597 (m), 1569 (s), 1528 (m), 1254 
(s), 1129 (s), 1074 (m); 1H NMR (300 MHz, DMSO-d6) δ / 
ppm: 11.20 (s, 1H, NH-3'), 10.27 (s, 1H, NH-Ac), 8.68 (s, 1H, 
NH2), 7.91 (s, 1H, NH2), 7.79 (d, 2H, J = 8.8 Hz, Ar), 7.71 (d, 
2H, J = 8.8 Hz, Ar), 7.16 (d, 1H, J6',5' = 7.8 Hz, H-6'), 5.28 (dd, 
1H, J5',6' = 7.8 Hz, J5',NH-3' = 2.1 Hz, H-5'), 3.81 (t, 2H, J3,2 = 6.4 
Hz, CH2-3), 2.57 (t, 2H, J2,3 = 6.4 Hz, CH2-2), 2.08 (s, 3H, CO-
CH3). 13C NMR (150 MHz, DMSO-d6) δ / ppm: 168.9 (s, CO-
CH3), 165.8 (s, C-4'), 163.6 (s, C-1), 150.7 (s, C-2'), 145.6 (d, 
C-6'), 142.6 (s, Ar) 136.1 (s, Ar), 127.2 (d, Ar), 118.4 (d, Ar), 
100.4 (d, C-5'), 45.2 (t, CH2-3), 34.8 (t, CH2-2), 24.1 (q, CO-
CH3). Anal. Calcd. mass fractions of elements, w / %, for 
C15H17N5O5S (Mr = 373.39) are: C, 47.49; H, 4.52; N, 18.46; 
S, 8.45; found: C, 47.19; H, 4.51; N, 18.09; S, 8.37. 
 
N1,N1-DIISOPROPYL-N2-(4-METHYLBENZENE-1-
SULFONYL)- 3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-
1(2H)-YL)PROPANAMIDINE (22) METHOD A 
White solid (53 %); m.p. = 210−213 °C; Rf = 0.41 (CH2Cl2 / 
MeOH 20 : 1); UV (MeOH): λmax / nm: 253 (log ε / dm–3 mol–1 
cm–1: 4.7); IR (KBr) ν / cm–1: 3172 (m), 3109 (w), 3029 (m), 
2976 (m), 2925 (m), 2829 (w), 1714 (s), 1679 (s), 1546 (s), 
1454 (s), 1400 (m), 1377 (s), 1454 (s), 1377 (s), 1344 (s), 
1261 (s), 1081 (s); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 
11.35 (s, 1H, NH-3'), 7.68 (d, 2H, J = 7.9 Hz, Ar), 7.45 (d, 1H, 
J6',5' = 7.8 Hz, H-6'), 7.35 (d, 2H, J = 7.9 Hz, Ar), 5.64 (d, 1H, 
J5',6' = 7.8 Hz, H-5'), 4.27 (m, 1H, CH-(CH3)2), 3.96 (t, 2H, J3,2 
= 7.1 Hz, CH2-3), 3.67 (m, 1H, CH-(CH3)2), 3.20 (t, 2H, J2,3 = 
7.1 Hz, CH2-2), 2.37 (s, 3H, CH3-Ts), 1.20 (brs, 12H, CH-
(CH3)2); 13C NMR (75 MHz, DMSO-d6) δ / ppm : 163.7 (s, C-
4'), 162.3 (s, C-1), 151.0 (s, C-2'), 144.9 (d, C-6'), 141.5 (s, 
Ar), 141.4 (s, Ar) 129.2 (d, Ar), 125.5 (d, Ar), 101.6 (d, C-5'), 
50.3 (d, CH-(CH3)2), 47.3 (d, CH-(CH3)2), 45.3 (t, CH2-3), 31.4 
(t, CH2-2), 20.9 (q, CH3-Ts), 20.1 (q, CH-(CH3)2), 19.6 (q, CH-
(CH3)2). Anal. Calcd. mass fractions of elements, w / %, for 
C20H28N4O4S (Mr = 420.52) are: C, 57.12; H, 6.71; N, 13.32; 
S, 7.62; found: C, 56.92; H, 6.79; N, 13.08; S, 7.74. 
 
N1-CYCLOPENTYL-N2-(4-METHYLBENZENE-1-SULFONYL)-
3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-1(2H)-
YL)PROPANAMIDINE (23) METHOD A 
White solid (39 %); m.p. = 181−184 °C; Rf = 0.60 (CH2Cl2 / 
MeOH 20 : 1); UV (MeOH): λmax / nm: 243 (log ε / dm–3 mol–1 
cm–1: 4.5); IR (KBr) ν / cm–1: 3330 (s), 3041 (m), 2966 (m), 
2869 (m), 2829 (w), 1697 (s), 1558 (s), 1267 (s), 1151 (s), 
1093 (s); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 11.24 (s, 
1H, NH-3'), 8.74 (d, 1H, J = 6.5 Hz, NH-cyclopentyl), 7.70 (d, 
2H, J = 7.8 Hz, Ar), 7.38 (d, 1H, J6',5' = 7.9 Hz, H-6'),  7.33 (d, 
2H, J = 7.8 Hz, Ar), 5.55 (d, 1H, J5',6' = 7.9 Hz, H-5'), 4.0 (t, 2H, 
J3,2 = 6.0 Hz, CH2-3), 3.98 (m, 1H, CH-cyclopentyl), 2.91 (t, 
2H, J2,3 = 6.0 Hz, CH2-2), 2.36 (s, 3H, CH3-Ts), 1.74 (m, 2H, 
CH2-cyclopentyl), 1.59–1.41 (m, 6H, CH2-cyclopentyl); 13C 
NMR (150 MHz, DMSO-d6) δ / ppm: 164.2 (s, C-4'), 163.8 (s, 
C-1), 150.7 (s, C-2'), 145.2 (d, H-6'), 141.5 (s, Ar), 141.4 (s, 
Ar), 129.2 (d, Ar), 125.6 (d, Ar), 101.0 (d, C-5'), 52.9 (d, CH-
cyclopentyl) 45.8 (t, CH2-3), 33.2 (t, CH2-2), 31.4 (t, CH2-
cyclopentyl), 23.5 (t, CH2-cyclopentyl), 20.9 (q, CH3-Ts). 
Anal. Calcd. mass fractions of elements, w / %, for 
C19H24N4O4S (Mr = 404.48) are: C, 56.42; H, 5.98; N, 13.85; 
S, 7.93; found: C, 56.15; H, 5.80; N, 13.47; S, 7.96. 
 
N1,N1-DIISOPROPYL-N2-(4-CARBOXYBENZENE-1-
SULFONYL)-3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-
1(2H)-YL)PROPANAMIDINE (24) METHOD C 
White solid (46 %); m.p. = 265 °C; Rf = 0.30 (CH2Cl2 / MeOH 
9 : 1); UV (MeOH): λmax / nm: 257 (log ε / dm–3 mol–1 cm–1: 
4.6); IR (KBr) ν / cm–1: 3213 (w), 3132 (w), 3109 (w), 2975 
(w), 2794 (w), 2611 (w), 2495 (w), 1546 (s), 1442 (m), 1375 
(s), 1276 (s), 1120 (m), 1083 (s), 788 (m), 705 (m), 628 (m), 
547 (m); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 13.30 (brs, 
1H, COOH), 11.34 (brs, 1H, NH-3'), 8.09 (d, 2H, J = 8.4 Hz, 
Ar), 7.90 (d, 2H, J = 8.4 Hz, Ar), 7.48 (d, 1H, J6',5' = 7.8 Hz, H-
6'), 5.63 (dd, 1H, J5',6' = 7.8 Hz, J5',NH-3' = 2.1 Hz, H-5'), 4.28 
(m, 1H, CH-(CH3)2), 3.97 (t, 2H, J3,2 = 7.5 Hz, CH2-3), 3.69 (m, 
1H, CH-(CH3)2), 3.22 (t, 2H, J2,3 = 7.5 Hz, CH2-2), 1.19 (pt, 
12H, J = 6.6 Hz, CH-(CH3)2); 13C NMR (75 MHz, DMSO-d6) δ / 
ppm: 166.3 (s, COOH), 163.7 (s, C-4'), 151.0 (s, C-2'), 147.5 
(s, Ar), 145.0 (d, C-6'), 133.3 (s, Ar), 129.8 (d, Ar), 125.7 (d, 
Ar), 101.6 (d, C-5'), 50.5 (d, CH-(CH3)2), 47.5 (d, CH-CH3), 
45.3 (t, CH2-3), 31.6 (t, CH2-2), 20.0 (q, CH-(CH3)2), 19.5 (q, 
CH-(CH3)2). Anal. Calcd. mass fractions of elements, w / %, for 
C20H26N4O6S × 0.25H2O (Mr = 455.01) are: C, 52.79; H, 5.87; 
N, 12.31; S, 7.05; found: C, 52.74; H, 6.19; N, 12.03; S, 7.12. 
 
N1-ISOPROPYL-N2-(4-CARBOXYBENZENE-1-SULFONYL)-3-
(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-1(2H)-
YL)PROPANAMIDINE (25) METHOD C 
White solid (37 %); m.p. = 186−188 °C; Rf = 0.22 (CH2Cl2 / 
MeOH 9 : 1); UV (MeOH): λmax / nm: 247 (log ε / dm–3 mol–1 
cm–1: 4.3); IR (KBr) ν / cm–1: 3271 (m), 3099 (m), 3051 (m), 
2972 (m), 2935 (w), 2875 (w), 1670 (s), 1548 (s), 1465 (m), 
1365 (s), 1269 (s), 1149 (s), 1089 (s); 1H NMR (300 MHz, 
DMSO-d6) δ / ppm: 13.30 (brs, 1H, COOH), 11.24 (brs, 1H, 
NH-3'), 8.83 (d, 1H, J = 7.2 Hz, NH-CH), 7.99 (d, 2H, J = 8.7 
Hz, Ar), 7.79 (d, 2H, J = 8.5 Hz, Ar), 7.40 (d, 1H, J6',5' = 7.8 Hz, 
H-6'), 5.55 (d, 1H, J5',6' = 7.8 Hz, H-5'), 4.04 (t, 2H, J3,2 = 6.1 
Hz, CH2-3), 3.87 (m, 1H, CH-(CH3)2), 2.92 (t, 2H, J2,3 = 6.1 Hz, 
CH2-2), 1.01 (d, 6H, J = 6.6 Hz, CH-(CH3)2); 13C-NMR (150 
MHz, DMSO-d6) δ / ppm: 163.3 (s, C-4'), 163.2 (s, C-1), 154.6 
(s, C-2'), 150.2 (s, Ar) 144.7 (d, C-6'), 140.2 (s, Ar), 128.8 (d, 
Ar), 124.6 (d, Ar), 100.5 (d, C-5'), 45.2 (t, CH2-3), 42.7 (d, CH-
(CH3)2), 32.8 (t, CH2-2), 20.6 (q, CH-(CH3)2). Anal. Calcd. 
mass fractions of elements, w / %, for C17H20N4O6S × 1.5H2O 
(Mr = 435.45) are: C, 46.89; H, 5.32; N, 12.86; S, 7.36; found: 
C, 46.53; H, 5.20; N, 12.48; S, 7.19. 
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N1-CYCLOPENTYL-N2-(4-METHYLBENZENE-1-SULFONYL)-
3-(2,4-DIOXO-3,4-DIHYDROPYRIMIDINE-1(2H)-
YL)PROPANAMIDINE (26) METHOD C 
White solid (42 %); m.p. = 190−193 °C; Rf = 0.30 (CH2Cl2 / 
MeOH 9 : 1); UV (MeOH): λmax / nm: 247 (log ε / dm–3 mol–1 
cm–1: 4.1); IR (KBr) ν / cm–1: 3255 (m), 3097 (m), 3037 (m), 
2964 (m), 2869 (m), 1620 (s), 1552 (s), 1469 (m), 1423 (m), 
1373 (s), 1282 (s), 1151 (s), 1087 (s); 1H NMR (300 MHz, 
DMSO-d6) δ / ppm: 13.48 (brs, 1H, COOH), 11.34 (s, 1H, NH-
3'), 8.99 (d, 1H, J = 6.4 Hz, NH-cyclopentyl), 8.15 (d, 2H, J = 
8.5 Hz, Ar), 8.00 (d, 1H, J6',5' = 7.9 Hz, H-6'), 7.47 (d, 2H, J = 
8.0 Hz, Ar), 5.63 (d, 1H, J5',6' = 7.9 Hz, H-5'), 4.12 (t, 2H, J3,2 = 
6.4 Hz, CH2-3), 4.10 (m, 1H, CH-cyclopentyl), 3.04 (t, 2H, J2,3 
= 6.4 Hz, CH2-2), 1.76 (m, 2H, CH2-cyclopentyl), 1.36 – 1.59 
(m, 6H, CH2-cyclopentyl); 13C NMR (150 MHz, DMSO-d6) δ / 
ppm: 164.2 (s, C-4'), 163.7 (s, C-1), 150.7 (s, CO-2'), 145.2 
(d, H-6'), 144.4 (s, Ar), 142.6 (s, Ar), 129.1 (d, Ar), 124.8 (d, 
Ar), 101.0 (s, C-5'), 52.9 (d, CH-cyclopentyl) 45.7 (t, CH2-3), 
33.2 (t, CH2-2), 31.4 (t, CH2-cyclopentyl), 23.5 (t, CH2-
cyclopentyl). Anal. Calcd. mass fractions of elements, w / %, 
for C19H22N4O6S (Mr = 434.46) are: C, 52.52; H, 5.10; N, 
12.89; found: C, 52.72; H, 5.14; N, 12.46. 
 
N1,N1-DIISOPROPYL-N2-(4-ACETAMIDOBENZENE-1-
SULFONYL)-3-(4-AMINO-4-OXOPYRIMIDINE-2(1H)-
YL)PROPANAMIDINE (27) METHOD A 
White crystals (45 %); m.p. = 232−235 °C; Rf = (CH2Cl2 / 
MeOH 9 : 1); UV (MeOH): λmax / nm: 265 (log ε / dm–3 mol–1 
cm–1: 4.4), IR (KBr) ν / cm–1: 3586 (m), 3342 (s), 3115 (m), 
2999 (m), 2974 (m), 1687 (s), 1663 (s), 1596 (m), 1552 (s), 
1535 (s), 1361 (s), 1249 (s), 1132 (s), 1085 (s); 1H NMR (300 
MHz, DMSO-d6) δ / ppm: 10.24 (s, 1H, NH-Ac), 7.73 (brs, 4H, 
Ar), 7.41 (d, 1H, J6',5' = 7.2 Hz, H-6'), 7.14 (brs, 2H, NH2), 5.74 
(d, 1H, J5',6' = 7.2 Hz, H-5'), 4.44 (m, 1H, CH-(CH3)), 3.91 (t, 
2H, J3,2 = 7.2 Hz, CH2-3), 3.66 (m, 1H, CH-(CH3)2), 3.14 (m, 
2H, CH2-2), 2.07 (s, 3H, CO-CH3), 1.21 (d, 6H, J = 6.5 Hz, CH-
(CH3)2), 1.18 (d, 6H, J = 6.5 Hz, CH-(CH3)2); 13C NMR (150 
MHz, DMSO-d6) δ / ppm: 168.8 (s, CO-CH3), 166.2 (s, C-4'), 
162.0 (s, C-1), 155.8 (s, C-2'), 145.3 (d, C-6'), 141.9 (s, Ar), 
138.2 (s, Ar), 126.5 (d, Ar), 118.4 (d, Ar), 94.1 (d, C-5'), 50.2 
(d, CH-(CH3)2), 47.3 (d, CH-(CH3)2), 46.6 (t, CH2-3), 31.6 (t, 
CH2-2), 24.1 (q, CO-CH3), 20.1 (q, CH-(CH3)2), 19.6 (q, CH-
(CH3)2); Anal. Calcd. mass fractions of elements, w / %, for 
C21H30N6O4S × H2O (Mr = 462.56) are: C, 52.48; H, 6.71; N, 
17.48; S, 6.67; found: C, 52.12; H, 6.39; N, 16.99; S, 6.56. 
 
N1,N1-DIETHYL-N2-(4-ACETAMIDOBENZENE-1-SULFONYL)-
3-(4-AMINO-4-OXOPYRIMIDINE-2(1H)-
YL)PROPANAMIDINE (28) METHOD A 
White crystals (50 %); m.p. = 208−210 °C; Rf = 0.23 (CH2Cl2 / 
MeOH = 9 : 1); UV (MeOH): λmax / nm: 264 (log ε / dm–3 mol–1 
cm–1: 3.8); IR (KBr) ν / cm–1: 3554 (m), 3434 (m), 3344 (m), 
3105 (m), 2977 (m), 2937 (m), 1701 (m), 1639 (s), 1560 (s), 
1527 (s), 1498 (s), 1365 (s), 1311 (s), 1251 (s), 1135 (s); 1H 
NMR (300 MHz, DMSO-d6) δ / ppm: 10.24 (s, 1H, NH-Ac), 
7.77 (d, 2H, J = 9.0 Hz, Ar), 7.71 (d, 2H, J = 9.0 Hz, Ar), 7.38 
(d, 1H, J6',5' = 7.2 Hz, H-6'), 7.13 (d, 2H, J = 20.1 Hz, NH2), 5.71 
(d, 1H, J5',6' = 7.2 Hz, H-5'), 3.92 (t, 2H, J3,2 = 7.6 Hz, CH2-3), 
3.55 (q, 2H, J = 6.8 Hz, CH2-CH3), 3.37 (q, 2H, J = 6.8 Hz, CH2-
CH3), 3,10 (t, 2H, J2,3 = 7.6 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 
1.15 (t, 3H, J = 6.9 Hz, CH2-CH3), 1.00 (t, 3H, J = 6.9 Hz, CH2-
CH3); 13C NMR (150 MHz, DMSO-d6) δ / ppm : 169.3 (s, CO-
CH3), 166.6 (s, C-4'), 163.7 (s, C-1), 156.2 (s, C-2'), 145.8 (d, 
C-6'), 142.5 (s, Ar), 138.7 (s, Ar), 127.0 (d, Ar), 118.8 (d, Ar), 
94.5 (s, C-5'), 47.2 (t, CH2-3), 43.5 (t, CH2-CH3), 43.4 (t, CH2-
CH3), 30.6 (t, CH2-2), 24.6 (q, CO-CH3), 14.4 (q, CH2-CH3), 
12.3 (q, CH2-CH3). Anal. Calcd. mass fractions of elements, 
w / %, for C19H26N6O4S × H2O (Mr = 452.52) are: C, 50.42; H, 
6.23; N, 18.57; S, 7.08; found: C, 50.75; H, 5.91; N, 18.21; S, 
7.27. 
 
N1-CYCLOPENTYL-N2-(4-ACETAMIDOBENZENE-1-
SULFONYL)-3-(4-AMINO-2-OXOPYRIMIDINE-2(1H)-
YL)PROPANAMIDINE (29) METHOD A 
White crystals (62 %); m.p. = 160−162 °C; Rf = 0.52 (CH2Cl2 / 
MeOH / EtOAc = 3 : 1 : 1); UV (MeOH): λmax / nm: 263 (log ε / 
dm–3 mol–1 cm–1: 4.5); IR (KBr) ν / cm–1: 3325 (m), 3097 (m), 
1653 (s), 1593 (s), 1537 (s), 1493 (s), 1445 (m), 1400 (m), 
1389 (m), 1371 (m), 1317 (m), 1261 (m), 1140 (s), 1086 (m); 
1H NMR (300 MHz, DMSO-d6) δ / ppm: 10.28 (s, 1H, NH-Ac), 
8.74 (d, 1H, J = 6.5 Hz, NH-cyclopentyl), 7.73 (q, 4H, J = 8.9 
Hz, Ar), 7.36 (d, 1H, J6',5' = 7.2 Hz, H-6'), 7.03 (d, 2H, J = 26.9 
Hz, NH2), 5.65 (d, 1H, J5',6' = 7.2 Hz, H-5'), 3.99 (t, 2H, J3,2 = 
6.3 Hz, CH2-3), 3.17 (s, 1H, CH-cyclopentyl), 2.94 (t, 2H, J2,3 
= 6.3 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.75 (m, 2H, CH2-
cyclopentyl), 1.45 (m, 6H, CH2-cyclopentyl); 13C NMR (75 
MHz, DMSO-d6) δ / ppm: 168.9 (s, CO-CH3), 166.0 (s, C-4'), 
164.3 (s, C-1), 155.6 (s, C-2'), 145.5 (d, C-6'), 141.9 (s, Ar), 
138.2 (s, Ar), 126.6 (d, Ar), 118.4 (d, Ar), 93.6 (d, C-5'), 52.9 
(d, CH-cyclopentyl), 46.6 (t, CH2-3), 33.5 (t, CH2-2), 31.4 (t, 
CH2-cyclopentyl), 24.1 (q, CO-CH3), 23.5 (t, CH2-
cyclopentyl). Anal. Calcd. mass fractions of elements, w / %, 
for C20H26N6O4S (Mr = 446.52) are: C, 53.8; H, 5.87; N, 18.82; 
S, 7.18; found: C, 50.75; H, 5.94; N, 18.65; S, 7.35. 
 
N1,N1-DIISOPROPYL-N2-(4-METYLBENZENESULFONYL)-3-
(4-(3-NITRO-1H-1,2,4-TRIAZOLE-1-YL)-2-OXO-3,4-
DIHYDROPYRIMIDINE-1(2H)-YL)PROPIONAMIDINE (30) 
To a stirred mixture of uracil derivative 15 (105.1 mg, 0.25 
mmol) in pyridine (1 mL) under argon, 1-(mesitylsulfonyl)-
3-nitro-1H-1,2,4-triazole) (MSNT) (265 mg, 1.14 mmol) and 
diphenylphosphate (30 mg, 0.12 mmol) were added. After 
stirring the reaction mixture for 48 hours at room 
temperature, the pyridine was evaporated and methanol 
(10 mL) was added. The product 30 precipitates from 
methanol as white crystals: 112 mg (86 %); Rf = 0.76 (CH2Cl2 / 
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MeOH = 20 : 1);  1H NMR (600 MHz, DMSO-d6) δ / ppm: 9.74 
(s, 1H, CH-triazole), 8.42 (d, 1H, J6',5' = 7.0 Hz, H-6'), 7.67 (d, 
2H, J = 8.0 Hz, Ar), 7.33 (d, 2H, J = 8.0 Hz, Ar), 7.08 (d, 1H, 
J5',6' = 7.0 Hz, H-5'), 4.37 (m, 1H, CH-(CH3)), 4.24 (t, 2H, J3,2 = 
7.5 Hz, CH2-3), 3.70 (brs, 1H, CH-(CH3)2), 3.34 (t, 2H, J2,3= 7.5 
Hz, CH2-2), 2.36 (s, 3H, CH3-Ts), 1.24 (dd, 12H, J = 6.4 Hz, J = 
3.3 Hz, 2×CH-(CH3)2); 13C-NMR (150 MHz, DMSO-d6) δ / 
ppm: 163.1 (s, C-4'), 161.5 (s, C-1), 158.2 (s, triazole), 154.3 
(d, C-6'), 154.1 (s, C-2'), 145.9 (s, triazole), 141.5 (s, Ar), 
141.3 (s, Ar), 129.2 (d, Ar), 125.5 (d, Ar), 94.2 (d, C-5'), 50.3 
(d, CH-(CH3)2), 48.2 (t, CH2-3), 47.4 (d, CH-(CH3)2), 31.1 (t, 
CH2-2), 20.9 (q, CH3-Ts), 20.1 (q, CH-(CH3)2), 19.6 (q, CH-
(CH3)2). 
 
N1-CYCLOPENTYL-N2-(4-METYLBENZENESULFONYL)-3-(4-
(3-NITRO-1H-1,2,4-TRIAZOLE-1-YL)-2-OXO-3,4-
DIHYDROPYRIMIDINE-1(2H)-YL)PROPIONAMIDINE (31) 
To a stirred mixture of uracil derivative 18 (100 mg,  
0.25 mmol) in pyridine (1 mL) under argon,  
1-(mesitylsulfonyl)-3-nitro-1H-1,2,4-triazole) (MSNT)  
(265 mg, 1.14 mmol) and diphenylphosphate (30 mg,  
0.12 mmol) were added. After stirring the reaction mixture 
for 48 hours at room temperature, the pyridine was 
evaporated and methanol (10 mL) was added. Product 
precipitates from methanol as white crystals 67 mg (56 %): 
Rf = 0.52 (CH2Cl2 / MeOH 20 : 1); 1H NMR (300 MHz, DMSO-
d6) δ / ppm: 9.75 (s, 1H, CH-triazole), 8.76 (d, 1H, J = 6.9 Hz, 
NH-cyclopentyl), 8.34 (d, 1H, J6',5' = 7.0 Hz, H-6'), 7.70 (d, 2H, 
J = 7.0 Hz, Ar),  7.32 (d, 2H, J = 7.4 Hz, Ar), 7.01 (d, 1H, J5',6' 
= 7.0 Hz, H-5'), 4.31 (t, 2H, J3,2 = 6.0 Hz, CH2-3), 4.00 (m, 1H, 
CH-cyclopentyl), 3.06 (t, 2H, J2,3= 6.0 Hz, CH2-2), 2.35 (s, 3H, 
CH3-Ts), 1.76 (m, 2H, CH2-cyclopentyl), 1.54 (m, 2H, CH2-
cyclopentyl), 1.45 (m, 2H, CH2-cyclopentyl), 1.38 (m, 2H, 
CH2-cyclopentyl); 13C-NMR (150 MHz, DMSO-d6) δ / ppm: 
163.9 (s, C-4'), 163.2 (s, C-1), 158.0 (s, triazole), 154.4 (d, C-
6'), 153.8 (s, C-2'), 145.8 (s, triazole), 141.5 (s, Ar), 141.4 (s, 
Ar), 129.2 (d, Ar), 125.6 (d, Ar), 93.5 (d, C-5'), 52.9 (d, CH-
cyclopentyl) 48.9 (t, CH2-3), 32.5 (t, CH2-2), 31.6 (t, CH2-
cyclopentyl), 23.5 (t, CH2-cyclopentyl), 20.9 (q, CH3-Ts). 
 
N1,N1-DIISOPROPYL-N2-(4-METYLBENZENESULFONYL)-3-
(4-AMINO-2-OXOPYRIMIDIN-2(1H)-YL)PROPANAMIDINE 
(32) 
To a suspension of compound 30 (77.8 mg, 0.15 mmol) in 
dioxane (3 mL) ammonium hydroxide (6 mL) was added. 
After stirring the reaction mixture for 24 hours at room 
temperature the solvent was evaporated under reduced 
pressure. The residue was purified by preparative 
chromatography (CH2Cl2/MeOH 9:1) to give product 32 as 
a white powder: 62 mg (98 %): m.p. = 220−222 °C; Rf = 0.47 
(CH2Cl2 / MeOH = 9 : 1); UV (MeOH): λmax / nm: 249 (log ε / 
dm–3 mol–1 cm–1: 4.3); IR (KBr) ν / cm–1: 3358 (m), 3099 (m), 
2972 (m), 1664 (s), 1645 (s), 1630 (s), 1545 (s), 1522 (s), 
1501 (s), 1447 (s), 1391 (s), 1371 (s), 1362 (s), 1252 (s), 1132 
(s), 1078 (s); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 7.70 (d, 
2H, J = 8.1 Hz, Ar), 7.41 (d, 1H, J6',5' = 7.2 Hz, H-6'), 7.36 (d, 
2H, J = 8.2 Hz, Ar), 7.13 (d, 2H, J = 9.0 Hz, NH2), 5.73 (d, 1H, 
J5',6' = 7.2 Hz, H-5'), 4.44 (m, 1H, CH-(CH3)2), 3.91 (m, 2H, 
CH2-3), 3.67 (brs, 1H, CH-(CH3)2), 3.15 (m, 2H, CH2-2), 2.37 
(s, 3H, CH3-Ts), 1.20 (dd, 12H, J = 10.7 Hz, J = 6.6 Hz, CH-
(CH3)2); 13C-NMR (150 MHz, DMSO-d6) δ / ppm: 166.2 (s, C-
4'), 162.1 (s, C-1), 155.8 (s, C-2'), 145.3 (d, C-6'), 141.5 (s, 
Ar), 141.4 (s, Ar), 129.3 (d, Ar), 125.5 (d, Ar), 94.1 (d, C-5'), 
50.2 (d, CH-(CH3)2), 47.3 (d, CH-(CH3)2), 46.6 (t, CH2-3), 31.8 
(t, CH2-2), 20.9 (q, CH3-Ts), 20.1 (q, CH-(CH3)2), 19.6 (q, CH-
(CH3)2). Anal. Calcd. mass fractions of elements, w / %, for 
C20H29N5O3S (Mr = 419.54) are: C, 57.26; H, 6.97; N, 16.69; 
S, 7.18; found: C, 57.40; H, 6.80; N, 16.65; S, 7.22. 
 
N1-CYCLOPENTYL-N2-(4-METYLBENZENESULFONYL)-3-(4-
AMINO-4-OXOPYRIMIDIN-2(1H)-YL)PROPANAMIDINE 
(33) 
To a suspension of compound 31 (50 mg, 0.1 mmol) in 
dioxane (2 mL) ammonium hydroxide (4 mL) was added. 
After stirring the reaction for 24 hours at room 
temperature the solvent was evaporated under reduced 
pressure. The residue was purified by preparative 
chromatography (CH2Cl2/MeOH 9:1) to give product 33 as 
a white powder: 27 mg (66 %); m.p. = 122 °C; Rf = 0.60 
(CH2Cl2 / MeOH 9 : 1); UV (MeOH): λmax / nm: 214 (log ε / 
dm–3 mol–1 cm–1: 4,2), λmax / nm: 238 (log ε / dm–3 mol–1 cm–1: 
4.2); IR (KBr) ν / cm–1: 3433 (s), 2923 (m), 2852 (m), 1714 
(s), 1652 (s), 1558 (s), 1496 (m) 1363 (s), 1267 (w), 1222 (w), 
1143 (m); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 8.84 (brs, 
1H, NH-cyclopentyl), 7.70 (d, 2H, J = 8.2 Hz, Ar), 7.39 (d, 1H, 
J6',5' = 7.2 Hz, H-6'), 7.32 (d, 2H, J = 8.2 Hz, Ar), 7.06 (d, 2H, J 
= 7.07 Hz, NH2), 5.66 (d, 1H, J5',6' = 7.2 Hz, H-5'), 4.00 (t, 2H, 
J3,2 = 6.2 Hz, CH2-3), 3.97 (m, 1H, CH-cyclopentyl), 2.94 (t, 
2H, J2,3 = 6.2 Hz, CH2-2), 2.35 (s, 3H, CH3-Ts), 1.60 (m, 8H, 
CH2-cyclopentyl); 13C NMR (150 MHz, DMSO-d6) δ / ppm: 
166.0 (s, C-4'), 164.3 (s, C-1), 155.6 (s, C-2'), 145.4 (d, C-6'), 
141.5 (s, Ar), 141.5 (s, Ar), 129.2 (d, Ar), 125.6 (d, Ar), 93.6 
(d, C-5'), 52.9 (d, CH-cyclopentyl) 45.6 (t, CH2-3), 33.5 (t, 
CH2-2), 31.4 (t, CH2-cyclopentyl), 23.5 (t, CH2-cyclopentyl), 
20.9 (q, CH3-Ts). Anal. Calcd. mass fractions of elements, w / 
%, for C19H25N5O3S (Mr = 403.5) are: C, 56.56; H, 6.25; N, 
17.36; S, 7.95; found: C, 56.40; H, 6.40; N, 17.22; S, 7.53. 
Cell Culturing and MTT Test[16] 
N-sulfonylamidino pyrimidine derivatives 1−28 were 
selected for preliminary in vitro cytotoxicity testing against 
normal Madine Darby canine kidney (MDCKI) cells, and 
seven tumor cell lines of different histological origin: cervix 
adenocarcinoma cells (HeLa), human epithelial colorectal 
adenocarcinoma cells (Caco-2), human caucasian 
bronchioalveolar carcinoma cells (NCI-H358), human 
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Burkitt lymphoma cells (Raji), human T cell lymphoma cells 
(HuT78), chronic myelogenous leukemia cells (K562) and 
human acute T cell leukemia cells (Jurkat). 
 The NCI-H358, Raji, HuT78, K562 and Jurkat cells 
were grown in RPMI 1640 medium (Gibco, EU) supple-
mented with 10 % heat-inactivated fetal bovine serum FBS 
(Gibco, EU), 2 × 10–3 mol dm–3 glutamine (Gibco, EU),  
1 × 10–3 mol dm–3 sodium pyruvate (Gibco, EU),  
1 × 10–2 mol dm–3 HEPES (Sigma-Aldrich, USA) and  
100 U/0.1 mg penicillin/streptomycin. The MDCKI, HeLa 
and Caco-2 cells were grown in Dulbecco’s Modified Eagle 
Medium DMEM (Gibco, EU), supplemented with 10 % FBS, 
2 × 10–3 mol dm–3 glutamine and 100 U / 0.1 mg 
penicillin/streptomycin; in tissue culture flasks and grown 
as monolayers. To detach them from the flask surface, cells 
were trypsinized using a 0.25 % trypsin/EDTA solution. Cells 
were cultured in a humidified atmosphere under the 
conditions of 37 oC / 5 % of CO2 gas in a CO2 incubator (Shell 
Lab, Sheldon Manufacturing, USA). 
 Tested compounds were dissolved in dimethyl 
sulfoxide as a 1 × 10–2 mol dm–3 stock solution. Working 
dilutions were prepared in high pure water at a 
concentration range 10–4–10–7 mol dm–3. 
 For the MTT test, the adherent cells, MDCK1, HeLa, 
and Caco-2, were seeded in 96 micro-well plates at 
concentration of 2 × 104 cells / cm3 and allowed to attach 
overnight in the CO2 incubator. After 72 hours of the 
exposure to tested compounds, medium was replaced with 
5 mg cm–3 MTT solution and the resulting formazane 
crystals were dissolved in DMSO. 
 Leukemia cells (1 × 105 cells ⁄ cm3), were plated onto 
96 micro-well plates and after 72 hours of incubation,  
5 mg cm–3 MTT solution was added to each well and 
incubated 4 hours in the CO2 incubator. To each well, 10 % 
SDS with 0.01 mol dm–3 HCl was added to dissolve water-
insoluble MTT-formazane crystals. The microplate reader 
(iMark, BIO RAD, Hercules, CA, USA) was used for 
measurement of the absorbance at 595 nm. All 
experiments were performed three times in triplicates.  
 The GI50 value, defined as the concentration of com-
pound achieving 50 % of cell growth inhibition was calcu-
lated and used to compare cytotoxicity among the 
compounds. Calculation of GI50 value curves and QC analy-
sis is performed by using the Excel tools and 
GraphPadPrism software (La Jolla, CA), v. 5.03. Briefly, indi-
vidual concentration effect curves are generated by plot-
ting the logarithm of the concentration of tested 
compounds (X) vs. corresponding percent inhibition values 
(Y) using least squares fit. The best fit GI50 values are calcu-
lated using Log (inhibitor) versus normalized response - 
Variable slope equation, where Y = 100 / (1 + 10^((log GI50-
X) * HillSlope)). QC criteria parameters (Z0, S:B, R2, 
HillSlope) were checked for every GI50 curve. 
RESULTS AND DISCUSSION 
Synthesis 
Cu(I)-catalyzed 1,3-dipolar cycloadditions of azides with 
terminal alkynes (CuAAC) afford a 1,4-disubstituted 1,2,3-
triazole. This powerful, widely used reaction[17,18] is the 
most representative example of click chemistry. 
Employment of electron-deficient phosphoryl or sulfonyl 
azides led to a path change in the copper-catalyzed reaction 
with 1-alkynes.[19] Proposed key intermediate ketenimine, 
which is generated in situ upon ring-opening of the 
corresponding copper-triazole intermediate, undergoes 
addition reactions with various nucleophiles such as 
amines, alcohols, water or heterocycle compounds to give 
amidines, imidates, amides and other coupled 
compounds.[20] These three component reactions allow 
access to biologically interesting compounds that are 
typically otherwise prepared by multistep functional group 
transformations. 
 The synthesis of target N-sulfonylamidino uracils 
15−26 was started by the preparation of 1-propargyl 
uracil.[21,22] First, the uracil was silylated with N,O-
bis(trimethylsilyl)acetamide (BSA) in acetonitrile and then 
the silylated intermediate was treated with propargyl 
bromide, giving the N-1 alkylated product in 64 % yield. 
 The copper-catalyzed reactions of 1-propargyl uracil 
with three different commercially available sulfonyl azides 
(4-acetamidobenzenesulfonyl, 4-methylbenzenesulfonyl 
and 4-carboxybenzenesulfonyl) and amines or amine salts 
were performed in THF or dichloromethane at room 
temperature affording N-sulfonylamidino uracils 15−26 in 
the 34−69 % yields (Table 1). All reactions included 20 % 
molar excess of sulfonyl azide and amine, except the 
reaction with 4-carboxybenzenesulfonyl azide (entry 12–
14), where a 100 % molar excess of amine was required. In 
the case of amine/ammonium salts (entry 10 and 11), 
additional triethylamine base in 50 % molar excess was 
used.[15] 
 Table 1 provides a comparison between the 
previously reported[15] N-sulfonylamidino thymine 
derivatives 1−14 and newly synthesized compounds from 
the uracil series 15−26. Compared to the propargyl 
thymine, in all reactions, a slightly lower reactivity of 
propargyl uracil is apparent, with the exception of 
compound 24 (entry 12, Table 1). Among used azides, 
reaction with 4-acetamidobenzenesulfonyl azide afforded 
products with highest yields.  
 As expected reactions of 1-propargyl uracil with  
4-acetamidobenzenesulfonyl azide or 4-methylbenzene-
sulfonyl azide (tosyl azide) and with secondary amines 
(Table 1, compounds 15, 16 and 22) gave better yields 
compared to those with primary amines (Table 1,  
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Table 1. Three-component coupling reactions of 1-propargyl thymine and 1-propargyl uracil with various aromatic sulfonyl 
azides, amines, and ammonium salts. 
N
H
H2N
N
H2N
NH4Cl
CNH2N
HCl
N
H
H2N
C
CH3
O
N
H
CH3
N
H
H2N
H2N
COOH
H2N
1
2
3
4
5
6
7
8
9
10
11
12
15       69(a)
16       57(a)
17       50(a)
18       48(a)
19       49(a)
20       34(b)
21       47(b)
22       53(a)
23       39(a)
24       46(c)
25       37(c)
26       42(c)
N3 S
25 oCO
O
N
R2 R
3
N S
O
O
R1
CuI
N
HN
O
OHN
R2
R3R1
     Entry              Azide-R1                    Amine            Product yield %(Ref.16,*)   Product yield %(*)
N
HN
O
O
R
NH4Cl
CNH2N
HCl
13
14
-          -
-          -
R
1        78(a)
2       64(a)
3       54(a)
4       58(a)
5        54(a)
6        45(b)
7        56(b)
8        54(a)
9        45(a)
12      43(c)
13      43(c)
14      45(c)
10      30(b)
11      39(b)
1-14, R = CH3 15-26, R = H
N
H
 
(*) Yields of analytically pure products. 
(a) Method A: alkyne (1 mmol), sulfonyl azide (1.2 mmol), amine (1.2 mmol), CuI (0.1 mmol) in THF (2.0 mL) at 25 °C for 24 h. 
(b) Method B: alkyne (1 mmol), sulfonyl azide (1 mmol), amine/ammonium salt (1 mmol), CuI (0.1 mmol) triethylamine (1.5 mmol) in CH2Cl2 (2−5 mL) at 25 °C for 
24 h. 
(c) Method C: alkyne (1 mmol), sulfonyl azide (1.2 mmol), amine (2 mmol), CuI (0.1 mmol) in THF (2.0 mL) at 25 °C for 24 h. 
(–) unreacted 1-propargyl uracil was isolated. 
 
 
 
ct yield /  [ ef. 15],* P  ield / (*)       try  Azide-R1  A i  
 
1 78(a) 
 
 
2 64(a) 
 
 
3 54(a) 
 
 
4 58(a) 
 
 
5 54(a) 
 
 
6 45(b) 
 
 
7 56(b) 
 
 
 
8 54(a) 
 
 
9 45(a) 
 
 
 
10 30(b) 
 
 
11 39(b) 
 
 
12 43(c) 
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25 37(c) 
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compounds 17, 18 and 23) and aromatic amine (Table 1, 
compound 19). The reactions with 4-carboxybenzene-
sulfonyl azide afforded products 24–26 in lower yields 
(Table 1, entry 12–14). A similar trend has been noticed for 
thymine series. A significant difference between the 
reactivity of propargyl uracil and propargyl thymine was 
observed since the preparations of the uracil analogs of 
compounds 10 and 11, failed. Although identical conditions 
were used, with the same reagents, there was no sign that 
the reaction occurred even at elevated temperatures, and 
the unreacted 1-propargyl uracil was isolated from the 
reaction mixture (> 90 %). 
 In the next step we decided to examine the 
conditions for the three-component coupling reactions 
with 1-propargyl cytosine, which was synthesized by the 
known condensation method of N4-acetylcytosine with 
propargyl bromide.[23] The cytosine amino group was 
acetylated with acetic anhydride in pyridine[24] and 
obtained N4-acetylcytosine was activated with K2CO3 in 
DMF and condensed with propargyl bromide. In the 
reaction mixture N1 and O2 regioisomers were obtained in 
the 96:4 ratio. N1 isomer was isolated by recrystallization 
from water and the acetyl group was readily removed by 
methanolic ammonia to give the desired N-1-propargyl 
cytosine. 
 Next, using the same conditions for Cu-catalyzed 
three-component reaction (Method A), 1-propargyl 
cytosine was reacted with 4-acetamidobenzenesulfonyl 
azide and secondary or primary amines giving desired 
products 27–29 in 45–62 % yields (Scheme 1). Cu-catalyzed 
three-component reactions of 1-propargyl cytosine and 
ammonium chloride (Method B) or 4-methylbenzene-
sulfonyl azide (Method A) failed to give any N-sulfonyl-
amidine product and the starting material, 1-propargyl 
cytosine, was completely recovered. 
 Then we decided to solve this problem by known 
transformations of uracil into cytosine derivatives.[25–28] In 
these methods, the C4 carbonyl group of the uracil 
derivative is converted to a leaving group (chlorine, 1,2,4-
triazole, etc.) which undergoes nucleophilic substitution 
with ammonia providing the corresponding cytosine 
derivative.  
 
N3 S 25 oC
O
O
N
R2 R3
N S
O
O
CuI
N
N
NH2
ON
N
NH2
O HN
R2
R3C CH3
O
N
H
C
CH3
O
N
H
27  R2= R3 =
29 R2 = H, R3 =
28  R2= R3 =
 
Scheme 1. Three-component coupling reactions of 1-propargyl cytosine [Method A: alkyne (1 mmol), sulfonyl azide  
(1.2 mmol), amine (1.2 mmol), CuI (0.1 mmol) in THF (2.0 mL) at 25 °C for 24 h]. 
 
 
N
R2 R3
N S
O
O
CH3
N
HN
O
O HN
N
N
N S
O
O
CH3
N
O
R2 R3
N
N
NO2
N
R2 R3
N S
O
O
CH3
N
N
NH2
O
MSNT, diphenyl phosphate
Py, Ar, rt
NH4OH/dioxane
15  R2= R3 =
18  R2 = H, R3 =
30  R2= R3 =
31 R2 = H, R3 =
32  R2= R3 =
33 R2 = H, R3 =
 
Scheme 2. Synthesis of N-sulfonylamidino cytosine 32 and 33 by transformations of uracil derivatives. 
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 The most successful method was with 1-(mesitylene-
2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT).[27] The N-sulfonyl-
amidino uracil derivatives 15 and 18 were treated with 
MSNT in the presence of diphenyl phosphate giving 
pyrimidine intermediates 30 and 31 in 86 % and 56 % yield, 
respectively. The latter compounds in the reaction with 
ammonium hydroxide in dioxane afforded desired  
N-sulfonylamidino cytosine derivatives 32 and 33 in 98 % 
and 66 % yield, respectively (Scheme 2). 
 In vitro Antiproliferative Screening 
We have shown before that N-1-sulfonylpyrimidine 
derivatives have strong and selective antiproliferative 
activity on different human tumor cell lines in vitro and on 
xenograft model in vivo.[5–10] Amidines are important units 
in chemistry for the synthesis of heterocycles[29,30] and 
widely used in bioactive chemicals and drug molecular 
design.[31–33] We assumed the improved antiproliferative 
capacity of novel hybrid compounds could be obtained if 
 
Table 2. Inhibitory effects of N-sulfonylamidine pyrimidine derivatives on the growth of normal and human tumor cells. 
GI50 (x 10–6 mol dm–3)(a) 
Comp. 
Normal cells Solid tumor cells Leukemia and lymphoma cells 
MDCK I HeLa Caco2 NCI-H358 Raji K562 HuT78 Jurkat 
1 > 100 > 100 > 100 > 100 > 100 > 100 > 100 54.1 ± 20.0 
2 8.3 ± 1.8 8.9 ±1.8 8.4 ± 1.2 17.0 ± 4.8 13.1 ± 3.3 16.1 ± 3.4 > 100 37.2 ± 4.2 
3 > 100 > 100 > 100 > 100 > 100 94.5 ± 6.4 > 100 76.7 ± 9.8 
4 > 100 > 100 > 100 > 100 > 100 > 100 85.4 ± 4.1 79.9 ± 7.6 
5 82.8 ± 17.8 > 100 > 100 > 100 > 100 > 100 > 100 44.8 ± 0.1 
6 11.0 ± 3.4 9.8 ± 1.7 11.0 ± 4.6 16.4 ± 3.8 13.9 ± 3.5 15.7 ± 2.8 > 100 39.2 ± 2.5 
7 > 100 > 100 > 100 > 100 > 100 > 100 > 100 61.9 ± 40.1 
8 10.4 ± 4.6 8.6 ± 0.5 12.2 ± 2.9 15.4 ± 1.3 13.6 ± 4.0 15.7 ± 2.8 > 100 38.2 ± 3.2 
9 9.0 ± 0.7 9.1 ± 2.0 10.8 ± 4.8 15.7 ± 3.6 12.8 ± 3.8 14.8 ± 0.6 > 100 38.0 ± 2.8 
10 8.0 ± 0.4 7.9 ± 0.9 9.6 ± 0.3 17.3 ± 5.7 12.6 ± 2.7 13.8 ± 3.2 > 100 37.6 ± 2.1 
11 > 100 52.9 ± 8.2 > 100 15.8 ± 3.1 69.9 ± 4.1 79.4 ± 26.0 > 100 38.3 ± 3.8 
12 9.8 ± 5.6 7.7 ±1.3 11.3 ± 7.2 > 100 72.1 ± 0 2.4 ± 0 7.1 ± 0 4.1  ± 0 
13 > 100 > 100 > 100 > 100 > 100 > 100 > 100 69.3 ± 0 
14 > 100 > 100 > 100 > 100 89.7 ± 0 62.1 ± 0 21.9 ± 0 27.8 ± 0 
15 > 100 > 100 > 100 > 100 85.4 ± 0 84.6 ± 4.1 > 100 57.5 ± 2.6 
16 9.0 ± 1.8 8.1 ± 1.9 13.2 ± 0.7 15.4 ± 2.7 19.1 ± 10.8 15.3 ± 3.4 > 100 36.5 ± 1.7 
17 > 100 > 100 > 100 > 100 75.3 ± 3.3 71.4 ± 37.0 79.9 ± 2.5 67.6 ± 23.1 
18 > 100 > 100 > 100 > 100 > 100 > 100 > 100 69.5 ± 8.5 
19 92.7 ± 5.6 > 100 > 100 > 100 77.0 ± 0 > 100 > 100 57.7 ± 13.9 
20 9.2 ± 1.2 9.0 ± 2.3 12.5 ± 4.2 16.0 ± 3.8 14.4 ± 4.2 15.7 ± 2.8 > 100 38.3 ± 0.8 
21 > 100 > 100 > 100 > 100 > 100 > 100 > 100 91.0 ± 3.3 
22 8.3 ± 1.0 11.3 ± 4.7 9.3 ± 0.8 17.9 ± 6.3 13.1 ± 3.3 15.3 ± 3.4 > 100 37.2 ± 4.2 
23 8.1 ± 0.1 11.0 ± 7.8 13.6 ± 0.8 18.0 ± 6.0 13.4 ± 2.9 15.6 ± 0.7 > 100 37.2 ± 1.8 
24 > 100 > 100 > 100 > 100 > 100 48.7 ± 0 24.9 ± 0 38.2 ± 0 
25 > 100 > 100 > 100 > 100 > 100 > 100 > 100 79.4 ± 8.8 
26 > 100 > 100 > 100 > 100 82.5 ± 21.8 54.1 ± 0 16.0 ± 0 68.4 ± 25.2 
27 11.3 ± 4.8 11.0 ± 4.2 18.2 ± 1.8 17.9 ± 6.0 15.6 ± 5.1 15.4 ± 2.1 > 100 37.9 ± 2.1 
28 7.4 ±0.8 10.7 ± 4.1 16.6 ± 3.7 17.3 ± 6.8 12.3 ± 3.1 14.9 ± 3.9 > 100 36.3 ± 2.6 
5-FU 55.1±3.3 8.2±1.9 5.9±0.7 8.0± 1.1 > 100 9.8±0.5 > 100 76.3± 11.4 
(a) GI50 – Compound concentration that inhibited cell growth by 50 %. Exponentially growing cells were treated with compounds during 72-h period. Cytotoxicity 
was analyzed using MTT survival assay. 
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the hybrids contain an amidine unit, a sulfonyl group, and a 
pyrimidine nucleobase in the same structure. 
 In this study, N-sulfonylamidino pyrimidine 
derivatives 1−28 were selected for preliminary in vitro 
cytotoxicity testing against normal MDCKI cells, carcinoma 
cells (HeLa, Caco-2, NCI-H358), two lymphoma cells (Raji, 
HuT78), leukemia cells (K562, Jurkat) and in a parallel with 
5-fluorouracil (5-FU) as a standard antitumor drug (Table 
2). All cells were treated by investigated compounds in the 
range of concentration 10–7–10–4 mol dm–3. 
 As indicated in Table 2, two large groups of prepared 
N-sulfonylamidine-derived pyrimidine analogues showed 
great variation in the antiproliferative effect on tumor cell 
lines, depending on the cell line and structure of the tested 
compounds.  
 The first group of N-sulfonylamidino derivatives of 
thymine (2, 6, 8, 9, 10), uracil (16, 20, 22, 23) and cytosine 
(27, 28), which share the same or similar chemical charac-
teristics and functional groups, shows strong antiprolifera-
tive effects on all treated cell lines. The GI50 ranged from 8 
to 41 × 10–6 mol dm–3 for MDCK I, HeLa, Caco-2, NCI-H358, 
Raji, K562 and Jurkat cells, with exception of HuT78 cells 
where antiproliferative activity of tested compounds in ap-
plied highest concentration of 1 × 10–4 mol dm–3 was not 
observed. 
 The most prominent difference in the antitumor ac-
tivity between thymine and uracil series was obtained be-
tween compounds 12 and 24, having the same N1 
substituent. The GI50 of normal MDCKI, tumor Caco-2, 
HeLa, HuT78, K562, and Jurkat cells induced by  
N-sulfonylamidino thymine 12 was between 2.4 × 10–6  
and 11.3 × 10–6  mol dm–3, whereas, as in the first group 
of tested compounds, antiproliferative activity on HuT78 
cells in applied highest concentration of 10–4 mol dm–3 
was not noticed. On the other hand, N-sulfonylamidino 
uracil 24 exhibits antiproliferative activity against 
lymphoma (HuT78 GI50 = 24.9 × 10–6 mol dm–3) and 
leukemia (K562: GI50 = 48.7 × 10–6  mol dm–3; Jurkat GI50 = 
38.2 × 10–6  mol dm–3) cell lines, while on normal (MDCK I) 
and tumor (HeLa, Caco2, NCI-H358, Raji) cell lines 
cytotoxic effects were not observed. 
 Compared to the first group of compounds, the 
second group of N-sulfonylamidino thymine (1, 3–5, 7, 13) 
and uracil (15, 17–19, 21, 25) derivatives, carrying the same 
N1 substituent, were mainly deprived of any inhibitory 
activities against the normal, solid tumor cell lines, 
leukemia and K562 lymphoma cell lines. Except compound 
5 (GI50 = 44.8 × 10–6 mol dm–3), all of them showed very 
weak antiproliferative capacity on the Jurkat cells (GI50 ∼ 
60–100 × 10–6 mol dm–3).  
 In addition, N-sulfonylamidino thymine 14 displayed 
good cytostatic activities on Raji and Jurkat cell lines, with 
GI50 values 21.9 × 10–6 mol dm–3 and 27.8 × 10–6  mol dm–3, 
respectively, while its structural analogue with uracil (26) 
shows strong antiproliferative effect on Raji cells (GI50 = 
16.0 × 10–6  mol dm–3). 
 
CONCLUSIONS 
In conclusion, the series of new aliphatic N-sulfonylamidino 
pyrimidine derivatives incorporating nucleobase, N-
sulfonyl and amidine pharmacophores in the structure 
were synthesized by Cu(I)-catalyzed three-component 
coupling of 1-propargyl nucleobase, benzenesulfonyl 
azides and amines. New N-sulfonylamidino pyrimidine 
derivatives possess good inhibitory potential against tested 
tumor cells. These results stimulate further studies directed 
to investigate their mechanisms of action. 
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